Adresse

Avenue Blonden 76
B- 4000 Liège

studio@doubleffect.be

Nous

Pour réussir votre plan de communication, nous mixons la créativité avec un zeste d’originalité, un soupçon d’innovation, le tout saupoudré d’une bonne dose de technicité.

What Is The Purpose Of The Addyi Rems Patient-Provider Agreement Form

You`ll find complete prescriber information in the full field alert. Print this article or see it as a PDF here: Addyi: Information for Patient Sample Care Providers Introduction Agreement Forms This resource contains two patient agreement forms, the increased risk of hypotension and syncope associated with Addyi due to an interaction with alcohol are formed by: Ensure that prescription patients and pharmacists are trained in the increased risk of hypotension and syncope associated with Addyi due to an interaction with alcohol and the need to advise patients on this risk. Inform patients of the increased risk of hypotension and syncope associated with Addyi due to interaction with alcohol. 5 Raleigh, N.C – September 21, 2015 – Sprout Pharmaceuticals, Inc. (Sprout) today announced that prescription pharmacists and health pharmacies can now undergo training to be certified under the Addyi Risk Evaluation and Mitigation Strategy (REMS) program for prescribing or dispensing the drug. Addyi, the first FDA-approved treatment for the most common form of sexual dysfunction in women, is a non-hormonal pill once a day to treat the generalized hypoactivity sexual pleasure disorder (HSDD) acquired in pre-menopausal women. It is only available through certified health professionals and pharmacies that are registered in this program. 6 Addyi is indicated for HSDD Addyi is indicated for the treatment of pre-menopausal women who have acquired a generalized sexual hypoactivity disorder (HSDD) as characterized by low sexual lust that causes distress or interpersonal difficulties and is NOT due to: a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a drug or other substance. Addyi use restrictions are not indicated for the treatment of HSDD in postmenopausal women or men. Addyi is not indicated to improve sexual performance. 6 Additional information: Amy Rose Edelman 312-297-6912 media@sproutpharma.com www.npr.org/sections/health-shots/2015/08/18/432704214/addyi-fda-approves-drug-to-boost-womens-desire Sprout Pharmaceuticals has prepared a patient-supplier agreement signed by both parties.